XML 33 R22.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2019
Accounting Policies [Abstract]  
Schedule of Manufacturing and Other Contingent Milestone and Co-Development Payments

 

Manufacturing and Other Contingent Milestone and Co-Development Payments (in thousands):

 

 

 

March 31, 2019

 

Molgradex API manufacturer:

 

 

 

 

Achievement of certain milestones related to validation

    of API and regulatory approval of Molgradex

 

$

3,650

 

Molgradex nebulizer manufacturer:

 

 

 

 

Achievement of various development activities and

    regulatory approval of nebulizer utilized to administer

    Molgradex

 

 

7,635

 

Molgradex Japanese licensee:

 

 

 

 

Co-development and regulatory costs

 

 

750

 

Medical education and research foundation:

 

 

 

 

First commercial sale in the U.S. of Molgradex in treatment

    of NTM

 

 

500

 

Total manufacturing and other commitments

 

$

12,535